Anticoagulant drugs for patients with atrial fibrillation on dialysis: a systematic analysis and network meta-analysis
XF Shen, C Zhang, J Hu, T Zhang, B Ma - Frontiers in Pharmacology, 2023 - frontiersin.org
Objective: A lack of clarity persists regarding the efficacy and risks associated with direct oral
anticoagulants (DOACs) in end-stage renal disease (ESRD) patients with atrial fibrillation …
anticoagulants (DOACs) in end-stage renal disease (ESRD) patients with atrial fibrillation …
Effectiveness and safety of edoxaban compared with apixaban in elderly patients with nonvalvular atrial fibrillation: a real-world population-based cohort study
R Chiv, S Beradid, S Suissa, C Renoux - Stroke, 2024 - Am Heart Assoc
BACKGROUND: The very elderly (≥ 80 years) are at high risk of nonvalvular atrial
fibrillation and thromboembolism. Given its recent approval, the comparative effectiveness …
fibrillation and thromboembolism. Given its recent approval, the comparative effectiveness …
Unresolved issues in the use of direct acting oral anticoagulants
Introduction Currently approved direct oral anticoagulants (DOACs) target thrombin or
coagulation factor Xa. Administered in fixed doses without routine laboratory monitoring …
coagulation factor Xa. Administered in fixed doses without routine laboratory monitoring …
Direct Oral Anticoagulants' Consumption and Expenditure in the COVID-19 Pandemic in Russia and Clinical Practice Guidelines for Their Use
EA Baybulatova, MS Chenkurov, EA Korovyakova… - …, 2023 - mdpi.com
Background: The coronavirus pandemic has led to the creation of clinical guidelines by a
large number of professional medical communities. However, the quality and methodology …
large number of professional medical communities. However, the quality and methodology …
Back to the Future: Observational Studies and Anticoagulant Selection for Nonvalvular Atrial Fibrillation
M Gattellari - Stroke, 2024 - Am Heart Assoc
Direct oral anticoagulants (DOACs) have mostly lived up to their hype as game changers for
stroke risk prevention in nonvalvular atrial fibrillation. 1, 2 With up to 4 available DOACs, 3 …
stroke risk prevention in nonvalvular atrial fibrillation. 1, 2 With up to 4 available DOACs, 3 …
Situación actual de los anticoagulantes orales de acción directa en atención primaria de España. Posicionamiento de SEMERGEN en 2023
J Polo-García, V Pallarés-Carratalá… - Medicina de Familia …, 2024 - Elsevier
La anticoagulación oral es clave para disminuir el riesgo de ictus en la fibrilación auricular.
Aunque clásicamente los antagonistas de la vitamina K (AVK) se han empleado para este …
Aunque clásicamente los antagonistas de la vitamina K (AVK) se han empleado para este …
Use of apixaban in children awaiting heart transplantation
V Benvenuto, C Hartje‐Dunn, L Vo… - Pediatric …, 2024 - Wiley Online Library
Background The use of apixaban in the pediatric cardiac population is expanding. We
describe our apixaban dosing and monitoring strategy in children and young adults awaiting …
describe our apixaban dosing and monitoring strategy in children and young adults awaiting …
Effectiveness and safety of edoxaban compared with apixaban in elderly patients with nonvalvular atrial fibrillation: a population-based cohort study
R Chiv - 2023 - escholarship.mcgill.ca
Background: The very elderly (≥ 80 years) are at high risk of nonvalvular atrial fibrillation
(NVAF) and thromboembolism, as older age represents the most prominent risk factor for …
(NVAF) and thromboembolism, as older age represents the most prominent risk factor for …